Andrea Watters
Overview
Explore the profile of Andrea Watters including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
266
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stejerean-Todoran I, Gimotty P, Watters A, Brafford P, Krepler C, Godok T, et al.
Neuro Oncol
. 2022 Sep;
25(4):674-686.
PMID: 36054930
Background: Melanoma, the deadliest of skin cancers, has a high propensity to form brain metastases that are associated with a markedly worsened prognosis. In spite of recent therapeutic advances, melanoma...
2.
Hristova D, Fukumoto T, Takemori C, Gao L, Hua X, Wang J, et al.
J Invest Dermatol
. 2021 Dec;
142(7):1882-1892.e5.
PMID: 34883044
The upregulation of the adaptor protein NUMB triggers melanocytic differentiation from multipotent skin stem cells, which share many properties with aggressive melanoma cells. Although NUMB acts as a tumor suppressor...
3.
Atlas A, Seltzer E, Watters A, Riley B, Chan T
Med Sci Educ
. 2021 Aug;
31(2):969-977.
PMID: 34457937
Formal mentorship programs afford medical students research involvement, career guidance, and personal and professional development. We reviewed a total of 36 studies on mentorship in medical schools, 17 of which...
4.
Zou Y, Watters A, Cheng N, Perry C, Xu K, Alicea G, et al.
Cancer Discov
. 2019 Oct;
9(12):1720-1735.
PMID: 31578185
Brain metastasis, the most lethal form of melanoma and carcinoma, is the consequence of favorable interactions between the invading cancer cells and the brain cells. Peroxisome proliferator-activated receptor γ (PPARγ)...
5.
Basu S, Gnanapradeepan K, Barnoud T, Kung C, Tavecchio M, Scott J, et al.
Genes Dev
. 2018 Feb;
32(3-4):230-243.
PMID: 29463573
Mutant forms of p53 protein often possess protumorigenic functions, conferring increased survival and migration to tumor cells via their "gain-of-function" activity. Whether and how a common polymorphism in at amino...
6.
Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, et al.
Cell Rep
. 2017 Nov;
21(7):1953-1967.
PMID: 29141225
Therapy of advanced melanoma is changing dramatically. Following mutational and biological subclassification of this heterogeneous cancer, several targeted and immune therapies were approved and increased survival significantly. To facilitate further...
7.
Shannan B, Watters A, Chen Q, Mollin S, Dorr M, Meggers E, et al.
Oncotarget
. 2016 Jul;
7(34):54897-54912.
PMID: 27448973
Therapeutic strategies for the treatment of metastatic melanoma show encouraging results in the clinic; however, not all patients respond equally and tumor resistance still poses a challenge. To identify novel...
8.
Shannan B, Chen Q, Watters A, Perego M, Krepler C, Thombre R, et al.
Pigment Cell Melanoma Res
. 2016 Feb;
29(3):317-28.
PMID: 26850518
Targeted therapies for mutant BRAF metastatic melanoma are effective but not curative due to acquisition of resistance. PI3K signaling is a common mediator of therapy resistance in melanoma; thus, the...